Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study

Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the optimal drug sequence. Expansion of the arsenal of thera...

Full description

Bibliographic Details
Main Authors:	E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2021-12-01
Series:	Медицинский совет
Subjects:	breast cancer eribulin trastuzumab efficacy tolerance
Online Access:	https://www.med-sovet.pro/jour/article/view/6578

Similar Items

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
by: L. A. Tashireva, et al.
Published: (2022-01-01)

Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
by: A. V. Sultanbaev, et al.
Published: (2023-04-01)

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
by: I. V. Kolyadina
Published: (2021-10-01)

Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy
by: A. V. Zyuzyukina, et al.
Published: (2022-09-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS
by: P. V. Мazin, et al.
Published: (2017-05-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
by: Herleeyana Meriyani, et al.
Published: (2025-03-01)

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
by: Mengqian Ni, et al.
Published: (2024-09-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

Eribulin mesylate exerts antitumor effects via CD103
by: Kazumasa Oya, et al.
Published: (2023-12-01)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
by: Meng-Xia Su, et al.
Published: (2024-02-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)

Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
by: Mengya Feng, et al.
Published: (2024-12-01)

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
by: Lan Chen, et al.
Published: (2024-05-01)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
by: Takahiro Ishizaka, et al.
Published: (2023-06-01)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
by: Xuemei Xie, et al.
Published: (2023-02-01)

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
by: Matteo Giulietti, et al.
Published: (2024-03-01)

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
by: Wei Wen, et al.
Published: (2019-08-01)

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
by: Xinyu Gui, et al.
Published: (2023-08-01)

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer
by: Hibiki Udagawa, et al.
Published: (2023-01-01)

Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
by: Weiwei Huang, et al.
Published: (2024-02-01)

Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy
by: Goyal RK, et al.
Published: (2023-11-01)

Optical coherence tomography angiography for choroidal neovascularization in pathological myopia and neovascular age-related macular degeneration in combination with axial myopia in comparative analysis
by: E. A. Drozdova, et al.
Published: (2021-12-01)

Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trialResearch in context
by: Masato Takahashi, et al.
Published: (2024-08-01)

Comparison of the effectiveness of intraoperative radiotherapy with external beam radiotherapy in patients with early breast cancer
by: A. G. Manikhas, et al.
Published: (2024-03-01)

Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides
by: Søren Brøgger Christensen
Published: (2022-09-01)

Non-linear M -sequences Generation Method
by: Z. R. Garifullina, et al.
Published: (2011-06-01)

Experimental substantiation of the composition of gelatin mass for obtaining capsules with essential oils
by: E. I. Molokhova, et al.
Published: (2021-12-01)

VALVULAR BRONCHIAL BLOCKING IN TREATMENT OF RELAPSING SPONTANEOUS PHEUMOTHORAX IN THE PATIENT WITH PARASEPTAL PULMONARY EMPHYSEMA
by: O. V. Lovacheva, et al.
Published: (2014-04-01)

Public administration of higher education as a key to scientific and technological development
by: E. I. Shumskaya, et al.
Published: (2023-12-01)

Experience of the usage intraoperative radiation therapy in patients with early breast cancer
by: A. G. Manikhas, et al.
Published: (2022-09-01)

Integration Aspects of Using the ABC-method in Trade Organization
by: I. V. Bagaev, et al.
Published: (2019-01-01)

Clinical manifestations of familial exudative vitreoretinopathy in children with nucleotide sequence alterations in the FZD4 gene
by: L. A. Katargina, et al.
Published: (2022-01-01)

Prospective bacterial and fungal sources of hyaluronic acid: A review
by: E.V. Shikina, et al.
Published: (2022-01-01)

Meiosis, spermatogenesis and ultrastructure of the basement membrane of seminiferous tubules in patients with azoospermia
by: E. E. Bragina, et al.
Published: (2019-04-01)